Metsera, Inc. (MTSR)
NASDAQ: MTSR · Real-Time Price · USD
23.58
+1.90 (8.76%)
At close: Apr 23, 2025, 4:00 PM
23.10
-0.48 (-2.04%)
After-hours: Apr 23, 2025, 5:42 PM EDT

Company Description

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.

The company was incorporated in 2022 and is based in New York, New York.

Metsera, Inc.
Metsera logo
Country United States
Founded 2022
IPO Date Jan 31, 2025
Industry Biotechnology
Sector Healthcare
Employees 81
CEO Christopher Bernard

Contact Details

Address:
3 World Trade Center, 175 Greenwich Street
New York, New York 10007
United States
Phone 212 784 6595
Website metsera.com

Stock Details

Ticker Symbol MTSR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0002040807
ISIN Number US59267L1070
SIC Code 2834

Key Executives

Name Position
Christopher Whitten Bernard Co-Founder, President, Chief Executive Officer and Director
Dr. Clive A. Meanwell M.D., Ph.D. Co-Founder and Executive Chairman
Christopher J. Visioli Co-Founder, Chief Financial Officer and Chief Business Officer
Paul L. Berns Co-Founder and Lead Independent Director
Dr. Brian Hubbard Ph.D. Chief Scientific Officer
Dr. Gbolahan Amusa Benz C.F.A., M.D. Executive Vice President of Strategic Finance and Investor Relations
Daniel Hoey Chief Technical Operations Officer
Christopher Todd Cox Chief Legal Officer
Nancye Green Chief Experience Officer
Michael Donovan Chief Design Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 10-K Annual Report
Mar 26, 2025 8-K Current Report
Mar 10, 2025 8-K Current Report
Feb 10, 2025 SCHEDULE 13D Filing
Feb 5, 2025 SCHEDULE 13G Filing
Feb 4, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 3, 2025 8-K Current Report
Jan 31, 2025 424B4 Prospectus
Jan 30, 2025 EFFECT Notice of Effectiveness
Jan 29, 2025 CERT Certification by an exchange approving securities for listing